Loading
Liver Disease Diagnosis and Treatment · Journal article
Livers · September 4, 2026
A consensus or society position rather than new primary data.
This narrative review consolidates evidence that the intestinal microbiota modulates NAFLD/MASLD progression through functional dysbiosis and gut–liver axis mechanisms, including barrier dysfunction, lipopolysaccharide translocation, and altered microbial metabolite production. The authors conclude that while microbiota is a biologically plausible disease modifier, it is not yet validated as a standalone diagnostic or therapeutic target, and clinical translation requires longitudinal, multi-omics functional studies.
Narrative review. Published literature on gut microbiota and NAFLD/MASLD; populations studied encompass patients with NAFLD/MASLD and obesity, insulin resistance, type 2 diabetes, and cardiometabolic dysfunction.
Literature search yielded 200 results since 2023 on gut microbiota and NAFLD/MASLD No consistent microbial taxonomic signature has been reproduced across populations, disease stages, and methodological platforms Identified shared pathogenic mechanisms across different dysbiotic communities: epithelial barrier impairment, microbial translocation, LPS-TLR4 activation, bile acid remodelling, short-chain fatty acid alteration, endogenous ethanol generation, choline and TMAO metabolism, and tryptophan-indole signalling
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize gut microbiota as a biologically plausible disease modifier in NAFLD/MASLD but not yet apply it as a standalone diagnostic or therapeutic tool. Future practice changes will depend on longitudinal, mechanistically-focused clinical studies that move beyond inconsistent taxonomic signatures toward functional characterization.
A narrative review synthesizing current evidence on gut microbiota's role in NAFLD/MASLD pathogenesis, offering a functional framework for understanding dysbiosis and identifying gaps in clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize gut microbiota as a biologically plausible disease modifier in NAFLD/MASLD but not yet apply it as a standalone diagnostic or therapeutic tool. Future practice changes will depend on longitudinal, mechanistically-focused clinical studies that move beyond inconsistent taxonomic signatures toward functional characterization.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Non-alcoholic fatty liver disease (NAFLD), now largely encompassed by the metabolic dysfunction-associated steatotic liver disease (MASLD) framework, is a leading cause of chronic liver disease worldwide and is closely linked to obesity, insulin resistance, type 2 diabetes (T2D), and cardiometabolic dysfunction. Although hepatic lipid accumulation and metabolic injury remain central to its pathogenesis, increasing evidence implicates the intestinal microbiota as a modulator of disease onset and progression through the gut–liver axis. Objectives: This narrative review summarizes current evidence linking gut microbiota to NAFLD/MASLD, with emphasis on functional microbial alterations relevant to the gut–liver axis, disease severity, microbiota-related biomarkers, and microbiota-targeted interventions. Methods: The literature search for this narrative review was mainly performed using PubMed/MEDLINE (which produced 200 results since 2023). The search addressed the relationship between gut microbiota, NAFLD/MASLD, and gut–liver axis dysfunction. Results: Early studies mainly focused on disease-associated bacterial taxa; however, no consistent microbial signature has been reproduced across populations, disease stages, and methodological platforms. This limitation supports a shift from a taxonomic view of dysbiosis toward a functional interpretation. Different microbial communities may converge on shared pathogenic outputs, including impaired epithelial barrier integrity, microbial translocation, lipopolysaccharide-driven Toll-like receptor 4 activation, bile acid remodelling, altered short-chain fatty acid production, endogenous ethanol generation, choline and trimethylamine-N-oxide metabolism, and tryptophan-derived indole signalling. These mechanisms may influence hepatic steatosis, inflammatory activation, and fibrogenesis. Conclusions: Current data support the microbiota as a biologically plausible disease modifier, but not yet as a standalone diagnostic or therapeutic target; clinical translation will require longitudinal, multi-omics, and function-oriented studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.